Compare stocks

Cellectis S.A. is a biotechnology company specializing in gene-editing for cancer immunotherapy. It focuses on developing allogeneic CAR-T cell products designed to address various hematological and solid tumors using its proprietary TALEN gene editing technology. Founded in 1999, Cellectis is headquartered in Paris, France, and operates facilities in both France and the United States, enhancing its global research and development capabilities. The company's strategic positioning is characterized by its focus on creating off-the-shelf CAR-T therapies, aiming to reduce the complexity and cost associated with personalized CAR-T treatments, thereby broadening accessibility to advanced cancer therapies.

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.